Various Baxter Healthcare Products Recalled

August 19, 2026

The information on this site is not intended to take the place of your doctor or other healthcare professionals. It is a resource to help you make the best decisions and get the most from the medical services available to you. A licensed physician should be consulted for diagnosis and treatment of all medical conditions.

On Aug. 7, 2026, Baxter Healthcare Corporation initiated a voluntary recall of selected lots of Myxredlin® (insulin human), Cardene IV® (nicardipine hydrochloride), Nexterone® (amiodarone HCl), and multiple injectable famotidine, clindamycin, dexmedetomidine, vasopressin, vancomycin, pantoprazole, and daptomycin products due to the potential for contamination with a beta-lactam drug product. Products containing beta-lactam compounds may cause allergic reactions, including severe and potentially life-threatening hypersensitivity reactions, in individuals with beta-lactam allergies. For additional information regarding affected products, lot numbers and expiration dates, see the manufacturer's recall notice here.

Last updated: August 19, 2026

The information on this site is not intended to take the place of your doctor or other healthcare professionals. It is a resource to help you make the best decisions and get the most from the medical services available to you. A licensed physician should be consulted for diagnosis and treatment of all medical conditions.